Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater.

Slides:

Advertisements

Similar presentations

Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced.

Advertisements

IDH1 mutant glioma cells are sensitive to TMZ

Network protein vulnerability in EGFR TKI‐resistant cells and specific for EGFR‐mutated cells. Network protein vulnerability in EGFR TKI‐resistant cells.

A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.

MEL23 and MEL24 inhibit Mdm2 and p53 ubiquitination in cells.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic.

NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.

RAS/RAF pathway-activated ovarian cancer cells exhibit MEK dependence and synergistic induction of apoptosis with combined MEK/AKT inhibition. RAS/RAF.

Pioglitazone inhibits aromatase expression in human preadipocytes.

Bortezomib sensitivity correlates with basal NF-κB activity in KP lung adenocarcinoma cell lines. Bortezomib sensitivity correlates with basal NF-κB activity.

Volume 23, Issue 1, Pages (January 2013)

CHK1 downregulation upon ERG overexpression.

MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2 Ji-guang Zhang,

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Correlation of mouse gene expression with bacterial gene expression.

The BRD4 bromodomain is critical for expression of SASP genes.

Downregulation of SPRY4 expression is associated with FGFR1–FRS2 activation. Downregulation of SPRY4 expression is associated with FGFR1–FRS2 activation.

EGFR is intrinsically active in FGFR3-activated cell lines with combination efficacy from targeting both EGFR and FGFR3. EGFR is intrinsically active in.

Fig. 3. TKI sensitivity assessed by the MANO method.

Molecular Therapy - Nucleic Acids

Role of HER2 in mediating acquired resistance to EGFR inhibition.

Existence of a nuclear NFATc1–STAT3 complex in pancreatic cancer.

CCL5 and IL-6 promote RAS-driven lung cancer cell proliferation in 3D culture. CCL5 and IL-6 promote RAS-driven lung cancer cell proliferation in 3D culture.

Supplementary Figure 1 A B C SW620 HT29 SW620

AKT2, but not AKT1, is required for regulating survival of PTEN-deficient prostate tumor spheroids. AKT2, but not AKT1, is required for regulating survival.

Mechanism of piperlongumine induced Sp downregulation.

HIPK2 decreases the stability of Notch1-IC through proteasome-dependent degradation. HIPK2 decreases the stability of Notch1-IC through proteasome-dependent.

TRAF4 is required for EGFR activation in response to EGF stimulation.

Increased expression levels of CHIT1 in the patients with IPF where they correlate inversely with SMAD7. Increased expression levels of CHIT1 in the patients.

Expression of mutant EGFR and downstream signaling components in tumors of mice at survival endpoint. Expression of mutant EGFR and downstream signaling.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

Therapy-induced senescence of primary cells.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

BEZ235 induces MAPK signaling in a FOXO3A-dependent manner.

The effects of the FASN blocker C75 on cell growth and survival (A, E, and F), on expression/phosphorylation of PI3K and MAPK signaling proteins and on.

Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.

Gramicidin A (GA) decreases HIF protein expression in RCC cells.

ALDH1A3 is mainly responsible for the ALDH activity in two human cholangiocarcinoma lines. ALDH1A3 is mainly responsible for the ALDH activity in two human.

A, GP and GR epithelial tumor cells are equally responsive to gefitinib. A, GP and GR epithelial tumor cells are equally responsive to gefitinib. Equal.

Biological effects of BRAF silencing: growth curves of A375 (A) and ARO (B) cell lines in the absence or presence of doxycycline. Biological effects of.

ERK reactivation following EGFR TKI treatment.

Dysregulated NF-κB activation in Il1r8+/+/lpr and Il1r8−/−/lpr mice.

PKCζ is tyrosine phosphorylated by EGF and contributes to EGF-induced activation of ERK in Mef cells. PKCζ is tyrosine phosphorylated by EGF and contributes.

SY-1425 induces maturation in RARA-high AML

Carcinoma cell–secreted IL-1 induces PGE2 production in MSCs

Platinum-based chemotherapy increased TXNIP expression, and overexpression of TXNIP enhanced the effectiveness of this therapy. Platinum-based chemotherapy.

Changes in signal transduction pathway induced by gefitinib.

EGFR signaling regulates transcription of PDGFRβ gene.

FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung cancer cell lines. FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung.

Pdcd4 expression inhibits AP-1 transactivation.

Cell-cycle regulatory proteins were controlled by O-GlcNAc at FOXO3 S284 through MDM2. Cell-cycle regulatory proteins were controlled by O-GlcNAc at FOXO3.

A, cell number was assessed 96 hours after exposure to indicated treatment in indicated cell models. A, cell number was assessed 96 hours after exposure.

Induction of PARP cleavage (A) and activation of caspases (B) after treatment with a combination of TRAIL and cisplatin. Induction of PARP cleavage (A)

P53 restoration in a syngeneic transplant model of Mdm2Tg p53Neo/Neo CreER angiosarcoma. p53 restoration in a syngeneic transplant model of Mdm2Tg p53Neo/Neo.

Expression and induction of HER2 and HPSE in 231BMBC cells.

Effect of MIF siRNA on the production of MMP-13 induced by LPA

W. chinensis extract induces apoptosis in AR-dependent prostate cancer cells. W. chinensis extract induces apoptosis in AR-dependent prostate cancer cells.

Validation of MYC-driven drug responses.

Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.

Posttranslational phosphorylation of p53 by platinum drugs in ovarian tumor cells. Posttranslational phosphorylation of p53 by platinum drugs in ovarian.

RA-9 induces G2–M cell-cycle arrest and caspase-mediated apoptosis in ovarian cancer cells. RA-9 induces G2–M cell-cycle arrest and caspase-mediated apoptosis.

Association of TCTP with Pim-3 in human pancreatic cancer cell lines.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.

GCS-100 selectively kills KRAS-addicted lung tumors.

MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid cells. In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

Presentation transcript:

Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. A, indicated EGFR-mutant lung cancer cell lines were treated with (+TKI) or without (−TKI) 1 μM gefitinib (2 μM CL-387,785 for H1975 cells) for 24 hours and lysates were probed with the indicated antibodies. Red type indicates high BIM-expressing cells, blue indicates low BIM-expressing cells. B, BIM RNA levels were quantified by qRT-PCR, normalized to β-actin, and plotted against the amount of apoptosis induced by the TKI (over vehicle-control) as determined by annexin FACS. Both RNA values and apoptosis are the mean of at least 3 experiments (see Supplementary Table S1). For linear regression analysis, the r2 value was 0.83 and P = 0.0018. Anthony C. Faber et al. Cancer Discovery 2011;1:352-365 ©2011 by American Association for Cancer Research